Take notice of the fact that Congress is gunning for Avanir Pharmaceuticals (AVNR) right now, asking the company to explain the pricing for Nuedexta, a recently-approved treatment for pseudobulbar affect (PBA).
PBA is defined as a neurological condition that leads to spontaneous episodes of laughing and/or crying for which there is no other approved treatment.
Sales of Nuedexta have hardly hit the ground running during the commercial launch - although it's still way to early to judge how much of a success the product could become - so some investors may be concerned that any regulatory interference with the pricing of the drug could put even more of a damper on the future potential of Avanir's flagship product.
It's not my opinion that the Congress has enough healthcare overhaul momentum to mount a serious attack on the likes of Avanir and its pricing for drugs, but it's definitely not out of the question that at some point down the road Congress will step in and attempt to regulate prices, in my opinion.
CLICK HERE FOR FULL ARTICLE
